Stay updated on Taldefgrobep Alfa in SMA Clinical Trial
Sign up to get notified when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.

Latest updates to the Taldefgrobep Alfa in SMA Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision: v3.4.3 updated to v3.5.0.SummaryDifference0.0%

- Check35 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No other content or functionality appears to be affected.SummaryDifference0.0%

- Check64 days agoChange DetectedAdded detailed extension phase dosing for taldefgrobep alfa and placebo, including open-label extension (OLE) phase. Updated the protocol to version 3.4.2 with related update dates (2026-01-30, 2026-02-04, 2026-06).SummaryDifference0.5%

- Check71 days agoChange DetectedNotice about government funding and operation status was added, and the page version updated from v3.4.0 to v3.4.1; these changes do not alter study details, eligibility criteria, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check78 days agoChange DetectedMinor UI/metadata updates: added Show glossary, Last Update Submitted that Met QC Criteria, Last Update Posted, No FEAR Act Data, and Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check114 days agoChange DetectedLocations sections were updated to include a comprehensive list of trial sites across multiple states and Scotland, with Revision: v3.3.3. Previous site groupings were removed/restructured.SummaryDifference2%

Stay in the know with updates to Taldefgrobep Alfa in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.